2024年6月3日 · Omontys (peginesatide) is used to treat anemia in people with chronic kidney disease who are on dialysis. Includes Omontys side effects, interactions and indications.

Peginesatide[2] (INN / USAN, trade name Omontys, formerly Hematide), developed by Affymax and Takeda, is an erythropoietic agent, a functional analog of erythropoietin.

OMONTYS is an erythropoiesis-stimulating agent (ESA) indicated for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis (1.1). In patients with CKD not on...

OMONTYS is given to treat anemia (low red blood cells) in adults with chronic kidney disease (CKD) who are on dialysis. OMONTYS stimulates your bone marrow to make more red blood …

2013年1月24日 · Peginesatide (Omontys, Affymax), a peptide-based ESA, 9,10 was approved in the United States in March 2012 for the treatment of anemia caused by chronic kidney disease …

2023年3月21日 · What Is Omontys? Omontys (peginesatide) is an erythropoietin indicated for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis. The …

2025年1月7日 · Omontys is used for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis. Omontys binds to and activates the human erythropoietin …

2012年3月27日 · OMONTYS is the only once-monthly erythropoiesis-stimulating agent (ESA) for anemia to be made available to the dialysis patient population in the United States.

OMONTYS is an erythropoiesis-stimulating agent (ESA) indicated for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis (1.1). In patients with CKD not...

2024年4月30日 · Learn about the side effects of Omontys (peginesatide), from common to rare, for consumers and healthcare professionals.